Publicacions (226) Publicacions de MIGUEL ARRABAL MARTÍN

filter_list

2024

  1. A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies

    OncoImmunology, Vol. 13, Núm. 1

  2. Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes

    Journal of Clinical Oncology, Vol. 42, Núm. 9, pp. 987-993

  3. Correlation between breast cancer subtypes determined by immunohistochemistry and n-COUNTER PAM50 assay: a real-world study

    Breast Cancer Research and Treatment, Vol. 203, Núm. 1, pp. 163-172

  4. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up ☆

    Annals of Oncology, Vol. 35, Núm. 2, pp. 159-182

  5. Efectividad de la estimulación del nervio tibial posterior en pacientes con vejiga hiperactiva resistentes al tratamiento médico

    Enfuro, Núm. 143, pp. 8-12

  6. Estudio de factores de riesgo en la recidiva bioquímica precoz y persistencia de PSA en pacientes sometidos a prostatectomía radical por cáncer de próstata

    Actualidad médica, Tomo 109, Núm. 820, pp. 154-160

  7. Long-term patient-reported outcomes from monarchE: Abemaciclib plus endocrine therapy as adjuvant therapy for HR+, HER2-, node-positive, high-risk, early breast cancer

    European Journal of Cancer, Vol. 199

  8. Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer

    Journal of Clinical Oncology, Vol. 42, Núm. 9, pp. 994-1000

  9. Patient-reported outcomes in high-risk HR+ /HER2- early breast cancer patients treated with endocrine therapy with or without palbociclib within the randomized PENELOPEB study

    European Journal of Cancer, Vol. 196

  10. Prognostic value of HER2DX in early-stage HER2-positive breast cancer: a comprehensive analysis of 757 patients in the Sweden Cancerome Analysis Network—Breast dataset (SCAN-B)

    ESMO Open, Vol. 9, Núm. 3

  11. Trastuzumab deruxtecan in breast cancer

    Critical Reviews in Oncology/Hematology, Vol. 198

2023

  1. A randomized, double-blind, placebo-controlled clinical trial of the use of hydroxycitric acid adjuvant to shock wave lithotripsy therapy in patients with calcium stones. Stone fragmentation results

    Urolithiasis, Vol. 51, Núm. 1

  2. A systematic review of the efficacy of intravesical electromotive drug administration therapy for non-muscle invasive bladder cancer

    Urologic Oncology: Seminars and Original Investigations, Vol. 41, Núm. 4, pp. 166-176

  3. Adjuvant intravesical treatment in patients with intermediate and high-risk non-muscle-invasive bladder cancer with BCG versus MMC applied with COMBAT or EMDA. Results of a prospective study

    Journal of Cancer Research and Clinical Oncology, Vol. 149, Núm. 10, pp. 7453-7459

  4. Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer

    Annals of Oncology, Vol. 34, Núm. 9, pp. 783-795

  5. Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients

    Clinical Cancer Research, Vol. 29, Núm. 20, pp. 4166-4177

  6. Beyond October, Beyond Pink: A Year-Round Revelation for Women’s Breast Health

    Journal of Women's Health, Vol. 32, Núm. 11, pp. 1143-1146

  7. Complementary and alternative medicine in cancer patients: characteristics of use and interactions with antineoplastic agents

    Journal of Cancer Research and Clinical Oncology, Vol. 149, Núm. 7, pp. 2855-2882

  8. Conductive hyperthermic chemotherapy versus electromotive drug administration of mitomycin C as intravesical adjuvant treatment of patients with intermediate or high-risk non-muscle invasive bladder cancer

    Urologic Oncology: Seminars and Original Investigations, Vol. 41, Núm. 2, pp. 109.e1-109.e8

  9. Electromotive Drug Administration Chemotherapy with Mitomycin C Versus Bacillus Calmette-Guerin for the Treatment of Non-Muscle Invasive Bladder Cancer

    Bladder Cancer, Vol. 9, Núm. 2, pp. 159-166